arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CRESCENT BIOPHARMA, INC.

CBIO
$12.90 ▼ -0.99 (-7.09%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

CRESCENT BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -12.8% ↘
FCF / Share None
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-23.28M
↓ -53.7% —
Operating Margin Operating profit as % of sales
-90.1%
↓ -273.8% —
FCF / Share Free cash flow per share
$-7.91
↑ +51.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↓
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 56 quarters